CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Amgen Announces Positive Phase 3 Results For Dazodalibep In Sjögren's Disease

By Reuters News

Nov 11 (Reuters) - Amgen Inc AMGN.O:

  • AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE

  • AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE

  • AMGEN - GLOBAL PHASE 3 TRIAL SHOWS CLINICALLY MEANINGFUL IMPROVEMENTS IN SJÖGREN'S DISEASE

  • AMGEN - DAZODALIBEP REGIMENS MEET PRIMARY ENDPOINT AT WEEK 48 WITH SIGNIFICANT DISEASE ACTIVITY REDUCTION

  • AMGEN - 1,500 MG REGIMEN SHOWS 5.6-POINT ESSDAI REDUCTION VERSUS 3.8 FOR PLACEBO; ADJUSTED P<0.001

  • AMGEN - SERIOUS ADVERSE EVENTS AND DISCONTINUATIONS BALANCED ACROSS ALL TREATMENT GROUPS

  • AMGEN - DAZODALIBEP PATIENTS SHOW GREATER INCREASES IN STIMULATED SALIVARY FLOW VERSUS PLACEBO

  • AMGEN - NO IMBALANCE IN THROMBOEMBOLIC EVENTS OR INFECTIONS; MALIGNANCY RATES LOW AND COMPARABLE

Further company coverage: AMGN.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk